Results 11 to 20 of about 5,445 (182)

Tolvaptan

South Asian Journal of Cancer, 2014
AbstractHyponatremia is a common and often under-recogonised clinical problem in oncologic practice. The recogonition of the cause of hyponatremia and initiation of appropriate and timely intervention can prevent morbidity and improve treatment tolerance. This drug review aims at discussing the currently approved oral vaptanagent Tolvaptan.
Bharath Rangarajan, Vineetha Binoy, Sachin Sharatchandra Hingmire, Vanita Noronha   +3 more
openaire   +4 more sources

Right ventricular enlargement predicts responsiveness to tolvaptan in congestive heart failure patients with reduced ejection fraction

International Journal of Cardiology: Heart & Vasculature, 2018
Background: Tolvaptan is a vasopressin type 2 receptor antagonist used in heart failure (HF) with refractory diuretic resistance. However, since tolvaptan is also ineffective in some HF patients with reduced ejection fraction (HFrEF), the identification ...
Shinichi Nonin, Shinichi Iwata, Asahiro Ito, Soichiro Tamura, Ryoko Kitada, Yu Kawai, Sera Ishikawa, Atsushi Doi, Akihisa Hanatani, Minoru Yoshiyama   +9 more
doaj   +2 more sources

Tolvaptan for the treatment of the syndrome of inappropriate antidiuresis (SIAD) [PDF]

Therapeutic Advances in Endocrinology and Metabolism, 2023
The syndrome of inappropriate antidiuresis (SIAD), the commonest cause of hyponatraemia, is associated with significant morbidity and mortality. Tolvaptan, an oral vasopressin V2-receptor antagonist, leads through aquaresis to an increase in serum sodium
Ploutarchos Tzoulis, Gregory Kaltsas, Stephanie E. Baldeweg, Pierre-Marc Bouloux, Ashley B. Grossman   +4 more
doaj   +3 more sources

Tolvaptan induces body fluid loss and subsequent water conservation in normal rats

Journal of Pharmacological Sciences, 2022
We have recently reported that the urea osmolyte-associated water conservation system is activated in fluid loss models such as high salt-induced natriuresis, renal injury-induced impaired renal concentrating ability, or skin barrier dysfunction-induced ...
Satoshi Kidoguchi, Kento Kitada, Yoshihide Fujisawa, Daisuke Nakano, Takashi Yokoo, Jens Titze, Akira Nishiyama   +6 more
doaj   +2 more sources

Tolvaptan treatment improves survival of cirrhotic patients with ascites and hyponatremia [PDF]

BMC Gastroenterology, 2018
Background Although tolvaptan treatment improves hyponatremia, only few studies have investigated whether tolvaptan actually benefits the survival of cirrhotic patients.
Shuzhen Wang, Xin Zhang, Tao Han, Wen Xie, Yonggang Li, Hong Ma, Roman Liebe, Honglei Weng, Hui-Guo Ding   +8 more
doaj   +2 more sources

Utility and Safety of Tolvaptan in Cirrhotic Patients with Hyponatremia: a Prospective Cohort Study

Annals of Hepatology, 2017
Introduction and aim: Hyponatremia is common in patients with decompensated cirrhosis and is associated with increased mortality. Tolvaptan, a vasopressor V2 receptor antagonist, can increase free water excretion, but its efficacy and safety in cirrhotic
Ji-Dong Jia, Wen Xie, Hui-Guo Ding, Hua Mao, Hui Guo, Yonggang Li, Xiaojin Wang, Jie-Fei Wang, Wei Lu, Cheng-Zhong Li, Yimin Mao, Gui-Qiang Wang, Yue-qiu Gao, Bangmao Wang, Qin Zhang, Yan Ge, Vincent Wai-Sun Wong   +16 more
doaj   +2 more sources

Renal ultrasonography predicts worsening renal function in patients with heart failure under tolvaptan administration

ESC Heart Failure
Aims Renal dysfunction in patients with chronic heart failure predicts a poor prognosis. Tolvaptan has a diuretic effect in patients with chronic kidney disease and heart failure without adverse effects on renal function.
Nobukiyo Tanaka, Yoshio Furukawa, Takuya Maeda, Hiroki Ishihara, Kazuhiro Dan, Masanori Teramura, Kei Ichihashi, Tetsuro Takase, Yuya Takahashi, Daichi Tsuzura, Akira Shinoda, Masato Fujii, Hisashi Okada, Fumiharu Itabashi, Tomohiko Teramoto   +14 more
doaj   +2 more sources

Potential amelioration of liver function by low-dose tolvaptan in heart failure patients

Toxicology Reports
Aim: This study aimed to evaluate the relationships between the pharmacokinetics of tolvaptan and its metabolites (DM-4103 and DM-4107) and liver injury in heart failure patients, using relevant laboratory test values and markers of hepatocyte injury and
Yasuaki Mino, Kohei Hoshikawa, Takafumi Naito, Shunta Akutsu, Yumi Imoto, Emi Nakatsugawa, Masao Saotome, Yuichiro Maekawa, Junichi Kawakami   +8 more
doaj   +2 more sources

Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease [PDF]

, 2017
BACKGROUND: In a previous trial involving patients with early autosomal dominant polycystic kidney disease (ADPKD; estimated creatinine clearance, >= 60 ml per minute), the vasopressin V-2-receptor antagonist tolvaptan slowed the growth in total kidney ...
Torres, Vicente E., Olivier Devuyst, Bammens, Bert, REPRISE Trial Investigators, Perrone, Ronald D, Perrone, Ronald D., Sergeyeva, Olga, Chapman, Arlene B, McQuade, Robert D, Olga Sergeyeva, Robert D. McQuade, Devuyst, Olivier, Koch, Gary, Gansevoort, Ron T, Ron T. Gansevoort, Gary Koch, McQuade, Robert D., Czerwiec, Frank S., John Ouyang, Czerwiec, Frank S, Manunta, P, Vicente E. Torres, Torres, Vicente E, Ronald D. Perrone, Jaime D. Blais, Chapman, Arlene B., Blais, Jaime D., on behalf of the REPRISE Trial Investigators, Gesualdo, Loreto, Arlene B. Chapman, Gansevoort, Ron T., Ouyang, John, Blais, Jaime D, Frank S. Czerwiec   +33 more
core   +7 more sources

Tolvaptan in ADPKD Patients With Very Low Kidney Function [PDF]

, 2021
Introduction: Tolvaptan slowed estimated glomerular filtration rate (eGFR) decline in subjects with autosomal dominant polycystic kidney disease (ADPKD) in TEMPO 3:4 and REPRISE trials.
Lee, Jennifer, Torres, Vicente E, Chapman, Arlene B, Japes, Hina, Gansevoort, Ron T, Perrone, Ronald D, Wang, Tao, Ouyang, John, Nourbakhsh, Ali   +8 more
core   +1 more source